Rizatriptan tablet versus wafer: Patient preference

After taking both conventional oral rizatriptan tablets and oral disintegra ting rizatriptan tablets in the treatment of migraine with or without aura, patients were permitted to select their formulation preference. All adult patients who had requested continuation of rizatriptan during a B-month per iod were included in the study. Of the 367 patients studied, 188 selected t he oral disintegrating tablet, while 179 preferred the conventional tablet. Although individual patients had strong preferences for one preparation ov er the other, no group preference was found.